HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: fj.07-9420comv1 22/4/1275    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by David, H. N. Articles by Abraini, J. H. PubMed PubMed Citation Articles by David, H. N. Articles by Abraini, J. H.

Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia

Hélène N. David^*,1, Benoit Haelewyn^*,1, Christophe Rouillon, Myriam Lecoq, Laurent Chazalviel, Gabriela Apiou, Jean-Jacques Risso, Marc Lemaire and Jacques H. Abraini^*,,2

^* NNOXe Pharmaceuticals, Québec, Quebec, Canada;

Centre CYCERON, UMR 6185, Université de Caen–Centre National de la Recherche Scientifique, Caen, France;

Air Liquide Research and Development, Centre de Recherche Claude-Delorme, Les Loges-en-Josas, France; and

Institut de Médecine Navale du Service de Santé des Armées, Toulon Naval, France

²Correspondence: Centre CYCERON, UMR 6185, Université de Caen CNRS, BP 5229, Boulevard Becquerel, 14074 Caen cedex, France. E-mail: abraini{at}cyceron.fr

Brain insults are a major cause of acute mortality and chronic morbidity. Given the largely ineffective current therapeutic strategies, the development of new and efficient therapeutic interventions is clearly needed. A series of previous investigations has shown that the noble and anesthetic gas xenon, which has low-affinity antagonistic properties at the N-methyl-D-aspartate (NMDA) receptor, also exhibits potentially neuroprotective properties with no proven adverse side effects. Surprisingly and in contrast with most drugs that are being developed as therapeutic agents, the dose-response neuroprotective effect of xenon has been poorly studied, although this effect could be of major critical importance for its clinical development as a neuroprotectant. Here we show, using ex vivo and in vivo models of excitotoxic insults and transient brain ischemia, that xenon, administered at subanesthetic doses, offers global neuroprotection from reduction of neurotransmitter release induced by ischemia, a critical event known to be involved in excitotoxicity, to reduction of subsequent cell injury and neuronal death. Maximal neuroprotection was obtained with xenon at 50 vol%, a concentration at which xenon further exhibited significant neuroprotective effects in vivo even when administered up to 4 h after intrastriatal NMDA injection and up to at least 2 h after induction of transient brain ischemia.—David, H. N., Haelewyn, B., Rouillon, C., Lecoq, M., Chazalviel, L., Apiou, G., Risso, J.-J., Lemaire, M., Abraini, J. H. Neuroprotective effects of xenon: a therapeutic window of opportunity in rats subjected to transient cerebral ischemia.

Key Words: oxygen-glucose deprivation • N-methyl-D-aspartate neurotoxicity • dopamine release • lactate dehydrogenase • neurological outcome